Clinical Trials
Cancer research helps find new ways to prevent, diagnose, treat, and manage all stages of cancer. Clinical trials are an important part of this process. When you take part in a clinical trial, you help researchers learn more about cancer and help make cancer care better for future patients.
To learn what your clinical trial options are, ask your oncologist whether there are any clinical trials that might be a good fit for you.
Learn More:
Visit the
It Starts with Me website for general information about clinical trials.
Clinical Trials available at THP
| DISEASE SITE | STUDY | PROTOCOL | clinicaltrials.gov LINK |
|---|
| BREAST | pionERA
(CO44657)
Roche
PI: Dr. Mala Bahl | Phase III, Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared with Fulvestrant, Both Combined with a CDK4/6 Inhibitor, in Patients with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer with Resistance to Prior Adjuvant Endocrine Therapy |
NCT06065748 |
| GI - HEPATOCELLULAR | HE.2
(SLIDE-HCC)
CCTG
PI: Dr. Mala Bahl | A Phase II Study of Stride (Durvalumab + Tremelimumab) with Lenvatinib Versus Stride Alone in Patients with Unrestectable Hepatocellular Carcinoma |
NCT06880523 |
| GU - PROSTATE | PCS XI
(CHU)
RADIATION
PI: Dr. Sarah Rauth | Pelvic nodes Ultra-Hypo Fractionated versus conventionally fractionated IMRT with HDR brachytherapy boost in prostate cancer: A collaborative multi-institutional non-inferiority phase 3 trial. |
NCT05820633 |
| GU - PROSTATE | PR.24
(ASCENDE-SBRT)
CCTG
PI: Dr. Jasper Yuen | Androgen Suppression Combined with Elective Nodal Irradiation and Dose Escalated Prostate Treatment: A Non-Inferiority, Phase III Randomized Controlled Trial of Stereotactic Body Radiation Therapy versus Brachytherapy Boost in Patients with Unfavourable Risk Localized Prostate Cancer |
NCT06235697 |
| GU - PROSTATE | PR.26
(TRIPLE-SWITCH)
CCTG
PI: Dr. Mary Mahler | A Randomized Phase III Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response |
NCT06592924
|
| GYNE - ADJUVANT ENDOMETRIAL | EN.10
(CCTG)
SURG/RADIATION
PI: Dr. Kate Pulman | A Phase II Study of Tailored Adjuvant Therapy in Pole-mutated And P53-wildtype/SNMP Early Stage Endometrial Cancer (RAINBO BLUE & TAPER)
SUBSTUDY A:
RAINBO POLEmut-BLUE: Refining Adjuvant treatment IN endometrial cancer Based On molecular features (RAINBO) TransPORTEC platform trials
SUBSTUDY B:
Tailored Adjuvant Therapy in p53-Wildtype/NSMP Early Stage Endometrial Cancer (TAPER) |
NCT05640999 |
| LUNG - METASTATIC NSCLC | MK-2870-007
(Merck)
PI: Dr. Daniel Yokom | A randomized, open-label, phase 3 study of MK-2870 in combination with pembrolizumab compared to pembrolizumab monotherapy in the first-line treatment of participants with metastatic non-small cell lung cancer with PD-L1 TPS greater than or equal to 50% (TroFuse-007) |
NCT06170788 |
